Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN DLBCL: Avelumab Combinations in R/R DLBCL
NCT02951156Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Dec 2016
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of avelumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities and Objective Response Rate up to 36 months. Started Dec 2016; status: terminated.
02
Drugs
avelumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02951156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02951156.